SIFI
↗Aci Sant'Antonio (Catania), Italy
SIFI is a leading international ophthalmic pharmaceutical company founded in 1935 in Catania, Sicily, and headquartered in Aci Sant'Antonio, Italy. The company specializes in the research, development, manufacturing, and commercialization of pharmaceutical products for the treatment and prevention of ocular pathologies, including cataracts, glaucoma, dry eye, corneal lesions, infections, and retinopathies. SIFI operates an integrated business model spanning research and development, manufacturing, and commercial distribution across pharmaceutical specialties, nutraceuticals, and ophthalmic cosmetics. The company has achieved significant international expansion with presence in over 60 countries and direct operations in major European markets, Mexico, and joint ventures in China and the UAE. SIFI's portfolio comprises over 50 pharmaceutical products and diagnostic/surgical instruments for eye care. The company generated revenues exceeding €100 million in 2024 with approximately 65% derived from international markets, demonstrating strong international commercial penetration.
CLASSIFICATION
SIZE & FINANCIALS
Employees:501-1000
Revenue:$100M-$150M (€100M+ in 2024)
Founded:1935
Ownership:subsidiary
Status:acquired
FUNDING
Stage:Mature/Private Equity Backed
Investors:21 Investimenti III Fund (21 Invest SGR S.p.A., founded by Alessandro Benetton)
PIPELINE
Stage:Commercial
Lead Drug Stage:EMA Approved (2024), FDA Anticipated Approval 2026
Modalities:Small molecule (eye drops), Pharmaceutical formulations (ointments, pills, capsules), Polymer/Biocide (polihexanide)
Active Trials:1
Trial Phases:Phase 4: 1
FDA Approvals:0
EMA Approvals:1
CORPORATE STRUCTURE
Parent Company:Faes Farma, S.A. (acquired June 2025)
Acquired By:Faes Farma, S.A. (2025-06-01)
Key Partnerships:Avanzanite Bioscience (exclusive distribution and commercialization of AKANTIOR in 26 European Economic Area countries and Switzerland), Polifarma (licensing agreement for marketing ophthalmology product portfolio in Italy), University of California, San Francisco (UCSF) - PUTT trial collaboration for Acanthamoeba Keratitis research (March 2025), Contract manufacturing partnerships with leading international pharmaceutical companies (€20M annual recurring revenue), Durbin (Early Access Program for AKANTIOR in acanthamoeba keratitis)
COMPETITION
Position:Leader
Competitors:Bausch & Lomb, Alcon, Allergan (AbbVie), Théa Pharmaceuticals, Santen Pharmaceutical, Horus Pharma, TearLab, Aciont
LEADERSHIP
Key Executives:
Fabrizio Chines - Chairman/President/CEO
Scientific Founders:Antonino Benanti, Carmelo Chines
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with SIFI. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.